Search

Your search keyword '"Xue, Liyan"' showing total 677 results
Start Over Author "Xue, Liyan"
677 results on '"Xue, Liyan"'

1. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial

Author

Qin, Jianjun, Xue, Liyan, Hao, Anlin, Guo, Xiaofeng, Jiang, Tao, Ni, Yunfeng, Liu, Shuoyan, Chen, Yujie, Jiang, Hongjing, Zhang, Chen, Kang, Mingqiang, Lin, Jihong, Li, Hecheng, Li, Chengqiang, Tian, Hui, Li, Lin, Fu, Junke, Zhang, Yong, Ma, Jianqun, Wang, Xiaoyuan, Fu, Maoyong, Yang, Hao, Yang, Zhaoyang, Han, Yongtao, Chen, Longqi, Tan, Lijie, Dai, Tianyang, Liao, Yongde, Zhang, Weiguo, Li, Bin, Chen, Qixun, Guo, Shiping, Qi, Yu, Wei, Li, Li, Zhigang, Tian, Ziqiang, Kang, Xiaozheng, Zhang, Ruixiang, Li, Yong, Wang, Zhen, Chen, Xiankai, Hou, Zhiguo, Zheng, Rongrong, Zhu, Wenqing, He, Jie, and Li, Yin

Published
2024
Full Text
View/download PDF

13. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC

Author

Li, Yong, Zhou, Aiping, Liu, Shuoyan, He, Ming, Chen, Keneng, Tian, Ziqiang, Li, Yin, Qin, Jianjun, Wang, Zhen, Chen, Haiquan, Tian, Hui, Yu, Yue, Qu, Wang, Xue, Liyan, He, Shun, Wang, Shuhang, Bie, Fenglong, Bai, Guangyu, Zhou, Bolun, Yang, Zhaoyang, Huang, Huiyao, Fang, Yan, Li, Benjamin, Dai, Xiangrong, Gao, Shugeng, and He, Jie

Published
2023
Full Text
View/download PDF

27. Research Progress of Predictive Markers for Efficacy of Immune Checkpoint Inhibitors for Esophageal Squamous Cell Carcinoma

Author

CHEN Rongshan and XUE Liyan

Subjects
immune checkpoint, tumor microenvironment, immunotherapy, biomarkers, esophageal squamous cell carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Esophageal squamous cell carcinoma (ESCC) is the main prevalent histological type of esophageal cancer worldwide, with a high mortality and poor prognosis due to advanced stage at diagnosis. Surgical resection after neoadjuvant therapy is the main treatment for ESCC. With the rise of immunotherapy, immunotherapy on ESCC has been shown to improve outcomes, especially the immune checkpoint inhibitors (ICIs). As the efficacy of immunotherapy for ESCC is limited, it is helpful to screen patients who may benefit from immunotherapy by looking for predictive biomarkers of efficacy of immunotherapy. In this paper, based on the current literature on immunotherapy and related biomarkers, we review the research progress on predictive markers of ICIs for ESCC, in hopes of providing assistances for the precise treatment and prognosis determination.

Published
2022
Full Text
View/download PDF

40. Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.

Author

Qi, Linlin, Jia, Jia, Zhang, Guochao, Liu, Jianing, Li, Fenglan, Chen, Jiaqi, Cui, Shulei, Cheng, Sainan, Xue, Liyan, Xue, Qi, and Wang, Jianwei

Subjects
EPIDERMAL growth factor receptors, VIRAL mutation, FISHER exact test, MUCINOUS adenocarcinoma, DIFFERENTIAL diagnosis, PLEURA
Abstract

Background: The aim of this study is to investigate the radiological features of primary pulmonary invasive mucinous adenocarcinoma (IMA) in a relatively large population to help improve its further understanding and its accuracy of initial diagnosis. Methods: This retrospective study included consecutive patients with pathologically confirmed primary pulmonary IMA from January 2019 to December 2021. According to tumor morphology, IMAs were divided into regular nodule/mass, irregular, and large consolidative types. According to tumor density, IMAs were divided into solid, halo, part‐solid, pure ground‐glass, and cystic types. ANOVA, chi‐square, or Fisher exact tests were used to analyze the differences in radiological and clinicopathological characteristics of IMA according to morphological and density subtypes. Results: We analyzed 312 patients. Pulmonary IMA tended to occur in the elderly, with a slightly higher number of women than men. IMA showed a predominance in the lower lobe and adjacent to pleura. IMA of regular nodule/mass, irregular, and large consolidative types accounted for 80.8% (252/312), 13.8% (43/312), and 5.4% (17/312), respectively. Solid, halo, part‐solid, pure ground‐glass, and cystic IMAs accounted for 55.8% (174/312), 28.2% (88/312), 11.2% (35/312), 1.3% (4/312), and 3.5% (11/312), respectively. The lobulated (76.9%), spiculated (63.5%), and air bronchogram (56.7%) signs were common in IMA. Dead branch sign (88.2%), angiogram sign (88.2%), and satellite nodules/skipping lesions (47.1%) were common in large‐consolidative‐type IMA. Kirsten rat sarcoma viral oncogene mutations were common (56.1%), whereas epidermal growth factor receptor mutations were relatively rare (2.3%). Conclusions: Pulmonary IMA of regular nodule/mass type and solid type were the most common at the initial diagnosis. Detailed radiological features can aid in the differential diagnosis of IMA. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results